TY - JOUR
T1 - Microdissection genotyping of gliomas
T2 - Therapeutic and prognostic considerations
AU - Mohan, Deepak
AU - Finkelstein, Sydney D.
AU - Swalsky, Patricia A.
AU - Sasatomi, Eizaburo
AU - Wiley, Clayton
AU - Hamilton, Ronald L.
AU - Lieberman, Frank
AU - Couce, Marta E.
PY - 2004/11
Y1 - 2004/11
N2 - Molecular anatomic pathology represents the blend of traditional morphological methods and the multigene approach to determine cancer-related gene alterations for diagnostic and prognostic purposes. Microdissection genotyping was utilized to characterize 197 gliomas with targeted microdissection of 2-7 areas spanning the spectrum of histologic types and grades. The methodology described herein is complementary to the existing realities of pathology practice. The technique utilizes paraffin-embedded fixative-treated tissue of small sample size after the primary morphological examination by the pathologist. Molecular information derived from microdissection genotyping in combination with the traditional histological information, results in an enhanced understanding of glioma formation and biological progression leading to improvements in diagnosis and prediction of prognosis. In all, 100% or 32 of 32 cases with at least partial treatment response was observed in neoplasms possessing the 1p or 1p/19q loss. The 19q loss alone without coexisting 1p showed no improvement in treatment response. Gliomas lacking 1p loss with only allelic loss involving 3p, 5q, 9p, 10q and 17p showed unfavorable outcome of only 35%, or six of 17 cases with treatment response. In addition, the determination of fractional allelic loss (favorable/unfavorable), was a very good independent predictor of biological behavior. These findings emphasize the importance of determining the cumulative pattern of mutational damage on 16 distinct sites or more, especially in the presence of 1p loss which in isolation or in combination with 19q is a favorable prognostic factor for therapeutic response.
AB - Molecular anatomic pathology represents the blend of traditional morphological methods and the multigene approach to determine cancer-related gene alterations for diagnostic and prognostic purposes. Microdissection genotyping was utilized to characterize 197 gliomas with targeted microdissection of 2-7 areas spanning the spectrum of histologic types and grades. The methodology described herein is complementary to the existing realities of pathology practice. The technique utilizes paraffin-embedded fixative-treated tissue of small sample size after the primary morphological examination by the pathologist. Molecular information derived from microdissection genotyping in combination with the traditional histological information, results in an enhanced understanding of glioma formation and biological progression leading to improvements in diagnosis and prediction of prognosis. In all, 100% or 32 of 32 cases with at least partial treatment response was observed in neoplasms possessing the 1p or 1p/19q loss. The 19q loss alone without coexisting 1p showed no improvement in treatment response. Gliomas lacking 1p loss with only allelic loss involving 3p, 5q, 9p, 10q and 17p showed unfavorable outcome of only 35%, or six of 17 cases with treatment response. In addition, the determination of fractional allelic loss (favorable/unfavorable), was a very good independent predictor of biological behavior. These findings emphasize the importance of determining the cumulative pattern of mutational damage on 16 distinct sites or more, especially in the presence of 1p loss which in isolation or in combination with 19q is a favorable prognostic factor for therapeutic response.
KW - 1p/19q
KW - Fractional allelic loss
KW - Glioma
KW - Loss of heterozygosity
KW - Microdissection genotyping
KW - Molecular anatomic pathology
UR - http://www.scopus.com/inward/record.url?scp=8144223994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8144223994&partnerID=8YFLogxK
U2 - 10.1038/modpathol.3800194
DO - 10.1038/modpathol.3800194
M3 - Article
C2 - 15181452
AN - SCOPUS:8144223994
SN - 0893-3952
VL - 17
SP - 1346
EP - 1358
JO - Modern Pathology
JF - Modern Pathology
IS - 11
ER -